Fig. 1. Flow cytometric histograms, morphology of hBMSC and efficacy and safety evaluation schedule. (A) FACS data of hBMSC. (B) Morphology of hBMSC and osteogenic, adipogenic differentiation lineage. (C) Experimental schedule. RA: renal artery, RA-C: renal artery control, RA-LD: renal artery low dose, RA-MD: renal artery moderate dose, RA-HD: renal artery high dose, TV-C: tail vein control, TV-LD: tail vein low dose, TV-MD: tail vein moderate dose, TV-HD: tail vein high dose, PSA: plasma solution A, hBMSC: human bone marrow-derived mesenchymal stem cells.

International Journal of Stem Cells 2023;16:66-77 https://doi.org/10.15283/ijsc21146

© 2022 International Journal of Stem Cells